HIV drug resistance and mother-to-child transmission of HIV

Clinics in Perinatology

Volumn 37, Issue 4, 2010, Pages 825-842

  Weidle, Paul J ^a   Nesheim, Steven ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiretroviral resistance; HIV; Infant; Mother to child transmission

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; BREAST FEEDING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MILK LEVEL; DRUG PENETRATION; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PREGNANCY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIRUS GENE; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; BREAST FEEDING; DEVELOPED COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY;

EID: 78349261468     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.08.009     Document Type: Review

References (62)

1. Clavel F., Hance A.J. HIV drug resistance. N Engl J Med 2004, 350(10):1023-1035.
2. Hirsch M.S., Gunthard H.F., Schapiro J.M., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008, 47(2):266-285.
3. Johnson V.A., Brun-Vezinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009, 17(5):138-145.
4. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. May 24, 2010 Available at:, Accessed May 24, 2010. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
5. Cooper E.R., Charurat M., Mofenson L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002, 29(5):484-494.
6. Mofenson L.M., Lambert J.S., Stiehm E.R., et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. pediatric AIDS clinical trials group study 185 team. N Engl J Med 1999, 341(6):385-393.
7. Warszawski J., Tubiana R., Le C.J., et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French perinatal cohort. AIDS 2008, 22(2):289-299.
8. Mirochnick M., Siminski S., Fenton T., et al. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001, 20(8):803-805.
9. Mirochnick M., Thomas T., Capparelli E., et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009, 53(3):1170-1176.
10. Gingelmaier A., Kurowski M., Kastner R., et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006, 20(13):1737-1743.
11. Bauer G.R., Welles S.L., Colgrove R.R., et al. Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease. J Acquir Immune Defic Syndr 2003, 34(3):312-319.
12. Soto-Ramirez L.E., Rodriguez-Diaz R., Duran A.S., et al. Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Res Hum Retroviruses 2008, 24(6):797-804.
13. Muro E., Droste J.A., Hofstede H.T., et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr 2005, 39(4):419-421.
14. Delaugerre C., Chaix M.L., Blanche S., et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology 2009, 6:85.
15. Frenkel L.M., Wagner L.E., Demeter L.M., et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995, 20(5):1321-1326.
16. Persaud D., Palumbo P., Ziemniak C., et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007, 195(10):1402-1410.
17. Karchava M., Pulver W., Smith L., et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York state. J Acquir Immune Defic Syndr 2006, 42(5):614-619.
18. Parker M.M., Wade N., Lloyd R.M., et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr 2003, 32(3):292-297.
19. Cunningham C.K., Chaix M.L., Rekacewicz C., et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002, 186(2):181-188.
20. Paredes R., Cheng I., Kuritzkes D.R., et al. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS 2007, 21(15):2103-2106.
21. Paredes R., Cheng I., Kuritzkes D.R., et al. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. AIDS 2010, 24(1):45-53.
22. Shah S.S., Crane M., Monaghan K., et al. Genotypic resistance testing in HIV-infected pregnant women in an urban setting. Int J STD AIDS 2004, 15(6):384-387.
23. Weinberg A., Forster-Harwood J., McFarland E.J., et al. Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol 2009, 45(1):39-42.
24. Welles S.L., Bauer G.R., LaRussa P.S., et al. Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007, 44(3):329-335.
25. Eastman P.S., Shapiro D.E., Coombs R.W., et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS clinical trials group protocol 076. J Infect Dis 1998, 177(3):557-564.
26. Mandelbrot L., Landreau-Mascaro A., Rekacewicz C., et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001, 285(16):2083-2093.
27. Palumbo P., Holland B., Dobbs T., et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001, 184(9):1120-1126.
28. Welles S.L., Pitt J., Colgrove R., et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS 2000, 14(3):263-271.
29. Lyons F.E., Coughlan S., Byrne C.M., et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005, 19(1):63-67.
30. Clarke J.R., Braganza R., Mirza A., et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 1999, 59(3):364-368.
31. Tubiana R., Le C.J., Rouzioux C., et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 2010, 50(4):585-596.
32. World Health Organization, UNICEF, UNAIDS Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. September 2009 progress report 2009, Geneva (Switzerland): World Health Organization, p. 1-162.
33. Bardeguez A.D., Shapiro D.E., Mofenson L.M., et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003, 32(2):170-181.
34. Eshleman S.H., Mracna M., Guay L.A., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001, 15(15):1951-1957.
35. Eshleman S.H., Jackson J.B. Nevirapine resistance after single dose prophylaxis. AIDS Rev 2002, 4(2):59-63.
36. Flys T., Nissley D.V., Claasen C.W., et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005, 192(1):24-29.
37. Flys T.S., Donnell D., Mwatha A., et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007, 195(5):711-715.
38. Lallemant M., Jourdain G., Le C.S., et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004, 351(3):217-228.
39. Lockman S., Shapiro R.L., Smeaton L.M., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007, 356(2):135-147.
40. Stringer J.S., McConnell M.S., Kiarie J., et al. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med 2010, 7(2):e1000233.
41. Chi B.H., Sinkala M., Mbewe F., et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007, 370(9600):1698-1705.
42. McIntyre J.A., Hopley M., Moodley D., et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009, 6(10):e1000172.
43. World Health Organization Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents November 2009, World Health Organization, Geneva (Switzerland): WHO Press, p. 1-26.
44. Eshleman S.H., Hoover D.R., Chen S., et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005, 19(18):2167-2169.
45. Guay L.A., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354(9181):795-802.
46. Arrive E., Newell M.L., Ekouevi D.K., et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007, 36(5):1009-1021.
47. Bedri A., Gudetta B., Isehak A., et al. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet 2008, 372(9635):300-313.
48. Kumwenda N.I., Hoover D.R., Mofenson L.M., et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med 2008, 359(2):119-129.
49. Kafulafula G., Hoover D.R., Taha T.E., et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010, 53(1):6-13.
50. Coovadia H.M., Rollins N.C., Bland R.M., et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007, 369(9567):1107-1116.
51. Hudelson S.E., McConnell M.S., Bagenda D., et al. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration. AIDS 2010, 24(4):557-561.
52. Thomas T., Masaba R., Ndivo R., et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mother in Kisumu, Kenya using highly active antiretroviral therapy: the Kisumu breastfeeding study [abstract]. In: 15th Conference on Retroviruses and Opportunistic Infectious (CROI) 2008.
53. Colebunders R., Hodossy B., Burger D., et al. The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk. AIDS 2005, 19(16):1912-1915.
54. Shapiro R.L., Holland D.T., Capparelli E., et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005, 192(5):720-727.
55. Bulterys M., Weidle P.J., Abrams E.J., et al. Combination antiretroviral therapy in African nursing mothers and drug exposure in their infants: new pharmacokinetic and virologic findings. J Infect Dis 2005, 192(5):709-712.
56. Zeh C., Weidle P.J., Nafisa L., et al. Emergence of HIV-1 drug resistance among breastfeeding infants born to HIV-infected mothers taking antiretrovirals for prevention of mother-to-child transmission of HIV: the Kisumu breastfeeding study, Kenya [abstract]. In: 15th Conference on Retroviruses and Opportunistic Infections 2010.
57. Macleod I.J., Rowley C.F., Thior I., et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol 2010, 48(2):162-167.
58. Kully C., Yerly S., Erb P., et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis 1999, 179(3):705-708.
59. Juethner S.N., Williamson C., Ristig M.B., et al. Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women. J Acquir Immune Defic Syndr 2003, 32(2):153-156.
60. Masquelier B., Chaix M.L., Burgard M., et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001, 27(2):99-104.
61. Fiscus S.A., Adimora A.A., Schoenbach V.J., et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 1999, 180(1):99-105.
62. Delaugerre C., Chaix M.L., Warszawski J., et al. [HIV-1 drug resistance in French infected-children: from newborn to adolescent]. Arch Pediatr 2007, 14(3):298-302.